Prevalence of Hepatitis B and Hepatitis C Infection and Their Associated Factors Among HIV-Infected Individuals in Same-Day Antiretroviral Therapy Initiation Program in Bangkok, Thailand

Background Viral hepatitis is highly prevalent among people living with HIV (PLHIV) and can lead to chronic liver complications. Thailand started universal hepatitis B vaccination at birth in 1992. We explored prevalence rates of hepatitis B and C and associated factors among PLHIV from same-day antiretroviral therapy (SDART) service at the Thai Red Cross Anonymous Clinic, Bangkok, Thailand. Methods We collected baseline characteristics from PLHIV enrolled in the SDART service between July 2017 and November 2019. Multivariate logistic regression was carried out to determine factors associated with positive hepatitis B surface antigen (HBsAg) and hepatitis C antibody (anti-HCV). Results We included a total of 4,011 newly diagnosed PLHIV who had HBsAg or anti-HCV results at baseline. Included were 2,941 men who have sex with men (MSM; 73.3%), 851 general population (21.2%), 215 transgender women (TGW; 5.4%), and 4 transgender men (0.1%). Median age was 27 years. Overall seroprevalence of HBsAg and anti-HCV were 6.0% and 4.1%, respectively. Subgroup prevalence rates were 6.2% and 4.7% among MSM, 4.6% and 2.4% among general population, and 9.3% and 3.7% among TGW. Factors associated with HBsAg positivity were being MSM (adjusted odds ratio [aOR] 1.64, 95% confidence interval [CI] 1.13 to 2.40), being TGW (aOR 2.87, 95% CI 1.60 to 5.17), birth year before 1992 (aOR 2.32, 95% CI 1.69 to 3.16), CD4 count 3 (aOR 1.38, 95% CI 1.03, 1.86), and alanine aminotransferase ≥ 62.5 U/L (aOR 2.39, 95% CI 1.66 to 3.43). Factors associated with anti-HCV positivity were being MSM (aOR 2.11, 95% CI 1.26 to 3.55), age > 30 years (aOR 1.54, 95% CI 1.10 to 2.17), alanine aminotransferase ≥ 62.5 U/L (aOR 7.74, 95% CI 5.48 to 10.9), creatinine clearance